Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Sanofi, Pozen to advance combination therapies
October 2013
SHARING OPTIONS:

PARISóSanofi has inked an exclusive license agreement with Pozen for the U.S. marketing of Pozen's combination therapies PA32540 and PA8140, which are under development for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. Per the terms of the agreement, Sanofi will be granted exclusive rights in the United States to commercialize all combinations of the drugs containing 325 mg or less of aspirin, and will pay Pozen $15 million up front. Pozen will be eligible for precommercial milestones of up to $20 million in addition to further milestones and sales royalties, and will be responsible for obtaining U.S. approval for the therapies. Sanofi will then be responsible for sales, marketing, ongoing manufacturing and future development.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
1000 N West Street, Suite 1200,
Wilmington, Delaware, 19801
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.